eSense-Lab Ltd. has been notified of approval from the Israeli Ministry of Health to allow testing of its proprietary TRP-ENV's compounds for efficacy against human coronavirus strain termed OC43 ("Coronavirus") and has signed a research agreement with the Central Virology lab of the MOH in Sheba Medical Center. OC43 is one of seven known coronaviruses to infect humans, including SARS-CoV-1, and SARS-CoV-2. Its molecular structure is identical to SAR-COV1/2 yet, its virulence is not as aggressive. Therefore, in the opinion of the Company, OC43 serves as the best model to reflect TRP-ENV anti-viral activity against SARS- COV2. The testing will provide peer-reviewed scientific evidence of the efficacy and spectrum of influence of the combined technologies. The research agreement covers testing of 16 formulations infused with TRP-ENV alone and in combinations with other active ingredients. The various formulations will be determined for their efficacy over various virus incubation times and their effectiveness against Coronavirus on a range of surfaces. The agreement with the MOH was internally generated by management of the Company and no fees were paid to anyone in relation to the agreement.